Akso Health Group

Company Overview

Business Model: Akso Health Group is a Cayman Islands holding company primarily focused on the healthcare sector. Its core business model involves the sale of medical devices in China, the provision of online hospital services, health consultancy, and online sales of medicines and health products in China, and marketing promotion services for the car insurance industry in China. Historically, the company operated in online microlending, P2P marketplaces, and social e-commerce, which have since been disposed of to focus on healthcare.

Market Position: The company is in a transitional phase, having recently pivoted to the healthcare sector. Its market position is currently developing, with recent strategic acquisitions aimed at establishing a presence in online healthcare services and medical device sales in China. The company plans significant expansion in the U.S. healthcare market with the establishment of vaccine research centers and radiation oncology centers, and in China with the acquisition of independent pharmacies. No specific market share data is disclosed.

Recent Strategic Developments:

• Acquisition of Tianjin Wangyi Cloud Co., Ltd.: Completed in November 2024, this acquisition for US$150 million provides Akso Health Group with 100% equity in a company operating online hospital services, health consultancy, and online sales of medicines/health products in China through its wholly-owned PRC subsidiaries, Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.
• Launch of Marketing Promotion Services: Commenced in April 2024 through Tianjin Wangyi Cloud Technology Co., Ltd., generating significant revenue in its first year.
• Planned U.S. Expansion: Strategic intent to establish and operate two vaccine research centers (AIDS, Covid-19) and 100 radiation oncology centers on the east coast of the U.S.
• Planned China Expansion: Intent to acquire multiple independent pharmacies nationwide in China.
• Disposal of Non-Core Businesses: The social e-commerce platform was disposed of in May 2023, following the disposition of online microlending and P2P marketplace businesses in December 2020, to fully concentrate on the healthcare sector.

Geographic Footprint: Akso Health Group's principal executive offices are located in Qingdao Pilot Free Trade Zone, China. Its operational presence spans China (Shandong, Tianjin provinces) and the United States (Wyoming, Massachusetts).

Cross-Border Operations: The company operates as a Cayman Islands holding company with a complex international subsidiary structure. Key subsidiaries are located in Hong Kong (Hexindai HK, We Healthy Limited, Akso Medi-care Limited), the British Virgin Islands (Akso Medical Cloud Limited), and the U.S. (WE HEALTH LIMITED, Akso First Health Treatment Center Inc., Akso Remote Medical Consultation Center Inc., Akso Online MediTech Co., Ltd.). Its primary operational entities are in China, including Qingdao Akso Health Management Co., Ltd. and the recently acquired Tianjin Wangyi Cloud Co., Ltd. and its subsidiaries. The functional currency for China operations is RMB, for U.S. operations is U.S. dollar, and the reporting currency is U.S. dollar.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: -1.9% (FY25), 5.1% (FY24)
• Operating Margin: -1125.4% (FY25), -357.8% (FY24)
• Net Margin: -916.7% (FY25), -377.6% (FY24)

Investment in Growth:

• R&D Expenditure: Not explicitly disclosed as a separate line item.
• Capital Expenditures: Net cash used in investing activities was US$105.9 million in FY25 and US$54.7 million in FY24.
• Strategic Investments: The company completed the acquisition of Tianjin Wangyi Cloud Co., Ltd. for a total consideration of US$150 million in FY25. This acquisition resulted in a goodwill impairment of US$41.4 million and a full impairment of acquired patents totaling US$121.1 million in FY25.

Currency Impact Analysis:

• The RMB depreciated approximately 8.3% against the U.S. dollar in FY23, 5.1% in FY24, and 0.5% in FY25.
• The company's functional currency is RMB for China operations and U.S. dollar for U.S. operations, with the U.S. dollar as the reporting currency.
• The effect of exchange rate changes on cash was a decrease of US$1,123,015 in FY25 and US$1,272,164 in FY24.
• No specific hedging strategies or effectiveness are disclosed.

Business Segment Analysis

Medical Devices Sales

Financial Performance:

• Revenue: US$0.4 million (FY25), US$2.4 million (FY24), US$13.2 million (FY23). This represents a significant year-over-year decline.
• Operating Margin: Gross Margin for medical devices was 2.9% in FY25 and 5.1% in FY24.
• Key Growth Drivers: Sales of medical devices like defibrillators (Class III) and anesthesia laryngoscopes (Class II) in China. Sales of COVID-19 Rapid Antigen test kits in the U.S. ceased at the end of 2022.

Product Portfolio:

• Major product lines include defibrillators (Class III) and anesthesia laryngoscopes (Class II).
• The company previously sold COVID-19 Rapid Antigen test kits in the U.S. market until the end of 2022.

Market Dynamics:

• Qingdao Akso Health Management Co., Ltd. holds a Class II Medical Device Selling Record Certificate in China. Its Class III Medical Device Operation License expired on March 2, 2022.
• Key supplier concentration: Brand Meditech (Asia) Company Limited accounted for 100.0% of medical device purchases in FY25.
• Key customer concentration: Qingdao New Xiekang Medical Technology Co., Ltd. accounted for 100.0% of medical device revenue in FY25.

Geographic Revenue Distribution:

• While not explicitly disaggregated by region for this segment, current operations are primarily focused on China through Qingdao Akso Health Management Co., Ltd.

Online Healthcare Services

Financial Performance:

• Revenue: Specific revenue figures for online healthcare services are not separately disclosed for FY25, as the acquisition of Tianjin Wangyi Cloud Co., Ltd. was completed in November 2024.
• Operating Margin: Not disclosed for this specific service.
• Key Growth Drivers: The company's revenue model for online healthcare services includes direct sales of health products, medical service fees (diagnosis, lab work, scans, consultation, treatments), collaborative profit-sharing with insurance partners, and technical/brand collaborations (medical software, APP services).

Product Portfolio:

• Major services include online hospital services, health consultancy, and online sales of medicines/health products.
• Tian Jin Deyihui Online Hospital Co., Ltd. holds a Medical Institution Practice License valid until August 20, 2028.

Market Dynamics:

• Operates in China through Tian Jin Deyihui Online Hospital Co., Ltd. and Tian Jin Deyihui Clinic Co., Ltd.
• Medical Insurance Bureau reimbursements typically take 60-90 days.
• Key customer relationships: Cooperative relationships have been established with Shiji Health Technology Co., Ltd. and Beijing Yimai Technology Co., Ltd., though business with these clients had not yet commenced as of the filing date.

Geographic Revenue Distribution:

• Operations are concentrated in China, specifically through the Tianjin-based subsidiaries.

Marketing Promotion Services

Financial Performance:

• Revenue: US$14.4 million in FY25, representing 97% of total revenue. This is a new revenue stream, commencing in April 2024.
• Operating Margin: Gross Margin for marketing promotion services was -2.0% in FY25.
• Key Growth Drivers: Commissions from insurance broker agencies for providing potential car insurance purchaser information.

Product Portfolio:

• The service involves generating and providing leads for car insurance purchasers to insurance broker agencies.

Market Dynamics:

• The business is influenced by seasonality, with higher activity typically observed in September and October due to vehicle sales.
• Supplier concentration: One supplier accounted for approximately 94.5% of total purchase costs for marketing promotion services and 92.0% of total costs of revenue in FY25.
• Customer concentration: Four clients accounted for 19.9%, 17.7%, 15.6%, and 10.1% of total revenue in FY25. Two clients accounted for 76.9% and 16.5% of total account receivable balance as of March 31, 2025.

Geographic Revenue Distribution:

• Operations are concentrated in China through Tianjin Wangyi Cloud Technology Co., Ltd.

International Operations & Geographic Analysis

International Business Structure:

• Subsidiaries: Akso Health Group (Cayman Islands) is the holding company. Key international subsidiaries include Hexindai HK (Hong Kong), WE HEALTH LIMITED (New York), We Healthy Limited (Hong Kong), Akso First Health Treatment Center Inc. (Massachusetts), Akso Remote Medical Consultation Center Inc. (Wyoming), Akso Online MediTech Co., Ltd. (Wyoming), Akso Medical Cloud Limited (BVI), Akso Medi-care Limited (Hong Kong). In China, key operating subsidiaries include Qingdao Akso Health Management Co., Ltd., Tianjin Akso Enterprise Management Co., Ltd., Tianjin Wangyi Cloud Co., Ltd., Tian Jin Deyihui Online Hospital Co., Ltd., and Tian Jin Deyihui Clinic Co., Ltd.
• Joint Ventures: No explicit joint ventures are disclosed.
• Licensing Agreements: The company acquired an Internet Hospital License as part of the Tianjin Wangyi Cloud Co., Ltd. acquisition.

Cross-Border Trade:

• Export Markets: Not explicitly detailed.
• Import Dependencies: Not explicitly detailed.
• Transfer Pricing: The company's international tax strategy includes considerations for transfer pricing policies and documentation requirements, particularly for inter-company transactions involving PRC subsidiaries.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: The company repurchased 1,165,883 ADSs for a total consideration of US$3,988,370, recorded as treasury stock. A share repurchase program of up to US$25 million was authorized in December 2018, but no further repurchases have occurred since.
• Dividend Payments: The company paid aggregated dividends of US$19,547,532 in FY19. No dividends have been declared or distributed since August 2018. An annual dividend policy (15-25% of anticipated net income after tax from PRC entities) was approved in July 2018, but no dividends were declared for FY23, FY24, and FY25.
• Dividend Yield: Not applicable due to no recent dividend payments.
• Future Capital Return Commitments: No specific future capital return commitments are disclosed beyond the existing, inactive dividend policy.

Balance Sheet Position:

• Cash and Equivalents: US$176.2 million as of March 31, 2025, a significant increase from US$85.2 million as of March 31, 2024.
• Total Debt: US$2.0 million, primarily from a related party loan with Webao Limited.
• Net Cash Position: US$174.2 million as of March 31, 2025.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The US$2.0 million related party loan is extended to August 26, 2025, at 0% annual interest.

Cash Flow Generation:

• Operating Cash Flow: US$1.2 million in FY25, US$1.4 million in FY24.
• Free Cash Flow: Not explicitly calculated or disclosed.
• Cash Conversion Metrics: Not explicitly detailed.

Currency Management:

• Cash holdings by major currencies: Not explicitly detailed, but RMB is not freely convertible.
• Natural hedging through operational diversification: Not explicitly detailed.
• Financial hedging instruments and strategies: Not explicitly detailed.

Operational Excellence

Production & Service Model:

• The company's model is primarily service-oriented and sales-driven. For medical devices, it involves selling products rather than manufacturing. For online healthcare, it focuses on service delivery through its online hospital and clinic platforms. Marketing promotion services are commission-based.

Global Supply Chain Architecture: Key Suppliers & Partners:

• Medical Devices: Brand Meditech (Asia) Company Limited is a critical supplier, accounting for 100.0% of medical device purchases in FY25.
• Marketing Promotion Services: One vendor accounted for approximately 94.5% of total purchase costs for marketing promotion services and 92.0% of total costs of revenue in FY25, indicating high supplier concentration.
• Technology Partners: Not explicitly detailed.

Facility Network:

• Manufacturing: Not applicable as the company is not a manufacturer.
• Research & Development: The company plans to establish two vaccine research centers (AIDS, Covid-19) in the U.S. Its R&D focus is on AI-driven health management solutions and big data analytics.
• Distribution: Not explicitly detailed beyond sales operations. The company leases office space and warehouses in Tianjin, China.

Operational Metrics:

• No specific capacity utilization, efficiency measures, or quality indicators are disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Implied for medical devices and online healthcare services.
• Channel Partners: For marketing promotion services, the company works with insurance broker agencies.
• Digital Platforms: The company operates a digital healthcare platform at https://www.dyihui.com/.

Customer Portfolio: Enterprise Customers:

• Medical Devices: Qingdao New Xiekang Medical Technology Co., Ltd. is a major client, accounting for 100.0% of medical device revenue in FY25.
• Online Healthcare: Shiji Health Technology Co., Ltd. and Beijing Yimai Technology Co., Ltd. are strategic partners for online healthcare services, though business had not yet commenced.
• Marketing Promotion Services: Four clients accounted for 19.9%, 17.7%, 15.6%, and 10.1% of total revenue in FY25, indicating significant customer concentration. Two clients accounted for 76.9% and 16.5% of total account receivable balance as of March 31, 2025.

Regional Market Penetration:

• Specific market share figures by region are not disclosed. The company's current market penetration is primarily in China for its healthcare and marketing services, with planned expansion in the U.S. healthcare market.

Risk Assessment Framework

Strategic & Market Risks

Global Market Dynamics:

• Policy Tightening: The company faces risks from policy tightening signals in the China healthcare sector, which contributed to the impairment of acquired intangible assets.
• Revenue & Profitability: Lower than expected revenue and profitability from the Tianjin Wangyi Cloud Co., Ltd. acquisition led to significant goodwill and intangible asset impairments.
• Customer Concentration: High customer concentration in both medical devices (one customer for 100% of revenue) and marketing promotion services (four customers for over 60% of revenue) poses a significant risk.

Operational & Execution Risks

Global Supply Chain Vulnerabilities:

• Supplier Dependency: The company has high supplier concentration, with one vendor accounting for 100% of medical device purchases and another for 92.0% of marketing promotion service costs in FY25, creating significant dependency and potential vulnerability to disruptions.
• Regional Disruptions: Not explicitly detailed, but operations in China are subject to local economic and political conditions.
• Trade Restrictions: Not explicitly detailed.

Financial & Regulatory Risks

Currency & Financial Risks:

• Foreign Exchange: Exposure to RMB depreciation against the U.S. dollar, as RMB is not freely convertible.
• Going Concern: The company reported a net loss of US$135.5 million in FY25 and US$9.5 million in FY24, with an accumulated deficit of US$198.9 million as of March 31, 2025. These conditions raise substantial doubt about the company’s ability to continue as a going concern, relying on increasing revenues, controlling expenses, and obtaining external financing.
• Credit & Liquidity: While recent financing activities have boosted cash reserves, the company's ability to generate sustained operational cash flows and access capital markets remains critical.

Regulatory & Compliance Risks:

• Multi-Jurisdictional Compliance: Operations in China and the U.S. necessitate compliance with diverse regulatory frameworks, including PRC Data Security Law, Personal Information Protection Law, and U.S. securities regulations.
• Trade Regulations: The company is subject to the Holding Foreign Companies Accountable Act (HFCA Act), though its auditor is PCAOB registered and subject to inspection. Future offerings will be subject to CSRC Overseas Listing Trial Measures.
• Licensing: Qingdao Akso Health Management Co., Ltd.'s Class III Medical Device Operation License expired in March 2022, which could restrict its ability to sell certain high-risk medical devices.

Geopolitical & External Risks

Country-Specific Risks:

• Political Risk (PRC): Uncertainties in the PRC legal system could limit the enforcement of contractual arrangements, potentially leading to government actions such as license revocation, operational restrictions, or fines.
• Economic Risk (PRC): Economic instability or currency devaluation in China could impact the company's operations and financial performance.
• Regulatory Changes (PRC): Changes in local laws, particularly concerning foreign investment restrictions or healthcare regulations, could affect the company's business model and expansion plans.

Innovation & Technology Leadership

Research & Development Focus: Global R&D Network:

• Planned U.S. R&D Centers: The company plans to establish two vaccine research centers (AIDS, Covid-19) on the east coast of the U.S.
• Innovation Pipeline: The company's R&D focus is on AI-driven health management solutions and big data analytics, aiming to enhance its digital healthcare platform.

Intellectual Property Portfolio:

• Patent Strategy: The company acquired patents as part of the Tianjin Wangyi Cloud Co., Ltd. acquisition, though these were fully impaired in FY25 due to policy tightening signals and lower than expected performance.
• Licensing Programs: The company holds an Internet Hospital License, acquired with Tianjin Wangyi Cloud Co., Ltd.
• IP Litigation: No specific IP litigation is disclosed.

Technology Partnerships:

• Strategic Alliances: Not explicitly detailed in the filing.
• Research Collaborations: Not explicitly detailed in the filing.

Leadership & Governance

Executive Leadership Team

International Management Structure:

• The company's organizational structure includes a network of subsidiaries across the Cayman Islands, Hong Kong, BVI, U.S., and China, indicating a multi-jurisdictional management framework. Specific details on regional leadership and reporting relationships are not provided.

Board Composition:

• The Board of Directors consists of five members (2 female, 3 male).
• Independent Directors include Stephen P. Brown (Audit committee financial expert), Zhe Liu, and Gerald (Jerry) T. Neal, satisfying NASDAQ independence requirements.
• The board oversees cybersecurity risks, reviewing related disclosures and updates quarterly.

Regulatory Environment & Compliance

Multi-Jurisdictional Regulatory Framework: Primary Regulatory Environments:

• Cayman Islands: Akso Health Group is not subject to income taxes in the Cayman Islands.
• Hong Kong: Subsidiaries We Healthy Limited and Akso Medi-care Limited are exempt from income tax on foreign-derived income.
• United States: U.S. subsidiaries are subject to federal and state income taxes, though no taxable income was reported for U.S. entities in FY25.
• PRC: PRC subsidiaries are subject to a statutory income tax rate of 25%. Dividends from PRC subsidiaries to Hong Kong subsidiaries may be subject to a 10% withholding tax, potentially reduced to 5% under the PRC-Hong Kong tax treaty if the Hong Kong entity holds at least 25% equity and is deemed a beneficial owner.

Cross-Border Compliance:

• Export Controls: Not explicitly detailed.
• Sanctions Compliance: Not explicitly detailed.
• Anti-Corruption: The company has adopted a code of business conduct and ethics, effective November 2017, applicable to directors, officers, employees, and advisors.
• Data Privacy: The company is subject to the PRC Data Security Law (effective Sept 1, 2021) and Personal Information Protection Law (effective Nov 1, 2021), imposing data security and privacy obligations. It is not currently subject to CAC cybersecurity review as it does not operate an online platform with over one million users' personal information.
• Securities Regulations: The company is an existing issuer under the CSRC Overseas Listing Trial Measures (effective March 31, 2023) and will be required to file for subsequent offerings. Its auditor, OneStop Assurance PAC (Singapore), is PCAOB registered and subject to inspection, addressing concerns under the Holding Foreign Companies Accountable Act (HFCA Act).
• Foreign Investment: Foreign investment in certain value-added telecommunication services in China (excluding e-commerce) is restricted to 50%. Hexin Digital holds EDI and ICP Licenses for e-commerce.
• SAFE Registration: PRC residents participating in overseas stock incentive plans are required to register with SAFE, and PRC resident beneficial owners have registered with the Beijing SAFE branch.

International Tax Strategy:

• Transfer Pricing: The company's international tax planning includes considerations for transfer pricing policies and documentation requirements for inter-company transactions.
• Tax Treaties: The PRC-Hong Kong tax treaty allows for reduced dividend withholding tax rates.
• BEPS Compliance: Not explicitly mentioned.

Currency Management & Financial Strategy

Multi-Currency Operations: Currency Exposure:

Hedging Strategies:

• The filing does not explicitly detail specific financial hedging instruments or strategies employed by the company to manage currency risks. The company's operational diversification across China and the U.S. may provide some natural hedging.